June 5th 2025
Valneva’s immunization, Ixchiq, was well tolerated in children ages 1 to 11 years regardless of the dose or previous chikungunya infection.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
CDC ACIP Meeting Examines Next Steps for Meningococcal, RSV, and Chikungunya Vaccination
April 16th 2025ACIP provides recommendations on meningococcal vaccines, RSV vaccination for at-risk adults, and chikungunya vaccines for travelers and laboratory workers, while also addressing safety concerns and potential expansions of use for each.
Read More